Low Ratio Relationship Detected Between Weight Loss Drugs and Breast Cancer Risk

A large-scale study conducted in the USA revealed remarkable findings regarding the relationship of GLP-1 class drugs used in the treatment of obesity and type 2 diabetes with the risk of breast cancer. The study found that breast cancer diagnosis rates may be lower in women using these medications. Data of More Than 111 Thousand Women Were Examined In the study conducted by researchers at the University of Pennsylvania Perelman School of Medicine, the health records of more than 111 thousand women between the ages of 45 and 80 were analyzed.

It was determined that approximately 15 thousand people among the participants received prescriptions for GLP-1 group drugs, while the remaining large group did not use these drugs. The data showed that the incidence of breast cancer may be approximately 35 percent lower in women using GLP-1. In addition, a similar decrease rate was recorded in comparisons made taking into account factors such as age, body mass index, ethnicity and diabetes status.

The Relationship Between Obesity and Breast Cancer The study pointed out that obesity is one of the known risk factors for breast cancer. Experts stated that it is important to examine the possible effect of weight loss drugs on this risk. Breast cancer is among the most common types of cancer in women. The team conducting the research and independent experts emphasized that the results obtained did not reveal a definitive causal relationship.

It was stated that some variables such as duration of drug use, species differences and genetic factors were evaluated in a limited way in the study. It was also stated that failure to identify all sources of drug use in data based on health records may affect the results. The research team announced that long-term clinical studies are planned to more clearly evaluate the effect of GLP-1 drugs on breast cancer. These studies are expected to include following women in high-risk groups for several years.